.png)
The shift to value-based care (VBC) models represents healthcare's most significant economic transformation in decades. Yet, for many organizations, one critical aspect remains stubbornly anchored in fee-for-service thinking: pharmacy operations.
"It's the ultimate blind spot,"
explains a Chief Population Health Officer at a major ACO.
"We've redesigned care models, revamped compensation, and rebuilt analytics – but we're still approaching pharmacy decisions with a fee-for-service mindset. The result is billions in unnecessary spending and missed opportunities to optimize both cost and outcomes."
This blind spot creates a particularly painful contradiction for organizations operating under both fee-for-service and value-based models. The same decision that maximizes revenue under fee-for-service could significantly increase medical loss ratios under risk-based contracts.
Traditional pharmacy operations focus on inventory management, dispensing efficiency, and maximizing reimbursement. Value-based pharmacy demands an entirely different approach:
One health system embracing this shift implemented an AI-powered pharmacy operations solution that could distinguish between fee-for-service and value-based patients at the point of care, applying different optimization criteria based on risk status.
Consider an actual case from this health system involving a Medicare patient requiring trastuzumab (Herceptin) treatment:
Before Implementation:
After Implementation:
Multiplied across thousands of high-cost medication decisions annually, this type of optimization yielded projected savings of $5 million annually – with no change in clinical outcomes.
Beyond pure cost considerations, the value-based pharmacy approach directly supports key quality metrics driving VBC performance:
"What's particularly powerful is that we're simultaneously improving financial performance and quality metrics,"
notes the system's VBC Program Director.
"This isn't about denying care – it's about making smarter choices about therapeutically equivalent options that align incentives across payers, providers, and patients."
For organizations operating in both reimbursement models, the challenges of dual optimization are particularly acute. The AI solution deployed by this health system could:
"What fascinated us was seeing the data on how often the 'right' choice differed between FFS and VBC patients,"
says the Chief Medical Officer.
"For the same medication class, the optimal selection might be completely different depending on risk arrangement. No human could possibly keep track of all those variables."
As VBC continues to expand, pharmacy operations are evolving from a tactical function to a strategic asset. Organizations leading in this transformation are taking several key steps:
The system's experience provides a glimpse into the future of pharmacy operations in a value-based world – one where medication decisions incorporate not just clinical factors, but also economic considerations aligned with the total cost of care.
"Five years from now, we'll look back at how we used to make medication decisions and be shocked at the waste and inefficiency,"
predicts the ACO's Director of Pharmacy.
"The idea that we weren't systematically optimizing one of our largest cost centers based on risk arrangement will seem incomprehensible."
For healthcare organizations navigating the transition to value-based care, reimagining pharmacy operations represents one of the most immediate, high-impact opportunities to align clinical practice with financial incentives – and AI-powered decision support at the point of care is proving to be the key enabler of this transformation.
As one physician summarized:
"For the first time, I can make decisions that are simultaneously best for my patient, best for the healthcare system, and best for our value-based contracts. That alignment has been elusive until now."
